Daniel Chung, the CEO of money-management company Alger, recommends investing in biotechnology and pharmaceutical companies for guaranteed investment growth.
According to Forbes, the CEO “is buying up companies like Gilead Sciences that use computer-aided analysis of the genome to produce targeted drugs for cancer and other diseases.”
Chung’s firm “believes these stocks can deliver higher sales and earnings regardless of global financial jitters. No growth trend lasts forever, of course, but Alger sees this trend persisting for at least three more years.”
Alger is investing in hospital companies as well, which will also see growth as a result of expanded healthcare coverage and the proliferation of technologies in medicine that increase efficiency.
Summary by MedicalGroups.com
To read more from Forbes, Click Here